Bedrijfsoverzicht
Retractable Technologies, Inc. is primarily engaged in the design, development, manufacturing, and marketing of safety syringes alongside other safety medical products tailored for the healthcare profession. This operational focus positions the entity within the Healthcare sector, specifically operating in the Medical Instruments & Supplies industry, which is characterized by stringent regulatory requirements and a demand for specialized, sterile equipment. The company currently holds a market capitalization of $20.06M and reported annual revenue of $38.27M for the trailing twelve months, while the specific employee count is not available in the provided data. These financial figures indicate that the company operates as a small-cap entity with a relatively modest revenue base, suggesting it holds a niche position within the broader medical device landscape rather than dominating a large market share.
Financiële gezondheid
For the trailing twelve months, the company generated revenue of $38.27M, yet recorded a net income of -$12,795,674 and an EBITDA of -$12,454,825, revealing a significant disparity between top-line sales and profitability that points to a cost structure where expenses substantially outweigh gross profits. The business reported free cash flow of -$2,183,980, indicating that operating cash generation is currently insufficient to cover capital expenditures and working capital needs, which limits the company's immediate financial flexibility to fund operations without external financing. Margin analysis shows a gross margin of 0.1%, an operating margin of -71.6%, and a profit margin of -32.8%, illustrating that after accounting for cost of goods sold and operating expenses, the company operates at a severe loss relative to its sales volume. The balance sheet displays $36.97M in cash against $1.20M in debt, resulting in a debt-to-equity ratio of 1.62, which suggests a leveraged capital structure despite the high cash balance, as the equity base appears diluted relative to liabilities. Liquidity is supported by a current ratio of 6.57, implying that the company possesses ample current assets to cover its short-term obligations, providing a buffer against immediate liquidity crises. However, the return on equity stands at -15.6% and the return on assets is -8.3%, metrics that reveal management has been ineffective at generating positive returns from the shareholders' capital and the asset base over the measured period.
Waarderingsbeoordeling
The trailing P/E ratio and forward P/E ratio are both listed as N/A due to the company's lack of positive earnings, a status that implies the traditional earnings-based valuation models are not applicable and that the market is pricing the stock based on non-earnings metrics or potential future profitability. The price-to-book ratio is 0.27, indicating that the market values the company's equity at a fraction of its book value, which often suggests the market perceives significant risks or impairment potential within the company's asset base. Alternative valuation metrics provide further context, with a price-to-sales ratio of 0.52 and an EV/EBITDA of 1.24, suggesting the company trades at a low multiple relative to its sales and enterprise value, reflecting a market expectation of continued struggles or a deep discount for the risks involved. The stock's price volatility is contextualized by a 52-week high of $1.14 and a 52-week low of $0.62; without a specific current share price provided in the facts, the trading range defines the historical bounds within which the asset has fluctuated over the last year. The beta value is 1.26, which indicates that the stock price tends to be more volatile than the broader market, moving with greater intensity in response to market-wide shifts compared to the average equity.
Growth & Income
The company achieved a revenue growth rate of 4.0% year-over-year, while earnings growth is N/A due to the absence of positive earnings, implying that top-line expansion is occurring without a corresponding improvement in profitability or bottom-line growth. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% payout ratio, meaning that all available cash flows are retained within the business rather than distributed to shareholders. This retention strategy implies that the company reinvests its limited cash resources, including the $36.97M cash on hand, into research, development, or operations in an attempt to bridge the gap between negative earnings and profitability. The overall growth and income profile is defined by modest top-line expansion paired with persistent losses and a lack of dividend income, presenting a high-risk, high-volatility investment characteristic typical of small-cap medical device firms attempting to navigate a path to sustained profitability.